Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial-Reference-Cited by-同舟云学术

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Published:2016-09 Issue:9 Volume:17 Page:1230-1239
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zielinski Christoph,Láng István,Inbar Moshe,Kahán Zsuzsanna,Greil Richard,Beslija Semir,Stemmer Salomon M,Zvirbule Zanete,Steger Günther G,Melichar Bohuslav,Pienkowski Tadeusz,Sirbu Daniela,Petruzelka Luboš,Eniu Alexandru,Nisenbaum Bella,Dank Magdalena,Anghel Rodica,Messinger Diethelm,Brodowicz Thomas

Publisher

Elsevier BV

Subject

Oncology

Reference15 articles.

1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

2. 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

3. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

4. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial;Lang;Lancet Oncol,2013

5. Obesity and outcomes in premenopausal and postmenopausal breast cancer;Loi;Cancer Epidemiol Biomarkers Prev,2005

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BATF promotes tumor progression and association with FDG PET-derived parameters in colorectal cancer;Journal of Translational Medicine;2024-06-11

2. Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study;Experimental and Therapeutic Medicine;2024-03-14

3. Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data;Oncology Research and Treatment;2024

4. Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting;Breast Care;2023-12-20

5. Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis;Cancer Pathogenesis and Therapy;2023-06